Harmony Biosciences Appoints Former Morgan Stanley Analyst Glenn Reicin as CFO

Harmony Biosciences Holdings, Inc. (HRMY) has announced the immediate appointment of Glenn Reicin as Chief Financial Officer. As a member of the Executive Team, Reicin will oversee the company's entire finance organization, including financial planning and analysis, accounting, treasury, investor relations, and risk management. The appointment coincides with a reiteration of the company's financial outlook. Harmony confirmed its 2026 net product revenue guidance, maintaining a projection between $1.0 billion and $1.04 billion. Reicin is a veteran biopharmaceutical executive with a career spanning both public and private sectors. He most recently served as CFO at Eccogene, where he was responsible for building the financial infrastructure necessary for IPO readiness. He also previously held the roles of CFO and COO at Alladapt Immunotherapeutics. Beyond his corporate leadership, Reicin spent 15 consecutive years as a top-ranked research analyst at Morgan Stanley and served as Managing Director of Skyline Ventures. His background in capital allocation and strategic planning is intended to drive the execution of Harmony's key strategic priorities. From a market perspective, the appointment of a seasoned financial leader combined with the stability of reiterated billion-dollar revenue guidance suggests a focus on operational maturity and sustained value creation for shareholders.